Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

	Application Number		10562087		
INFORMATION DIGGS COURT	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor John		in McGeachie		
(Not for submission under 37 CFR 1.99)	Art Unit		2167		
(NOTION CASEMISSION CHICAGO OF CHICAGO	Examiner Name Not		lot Yet Assigned		
	Attorney Docket Numb	er	58169-029		

				U.S.	PATENTS		Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevan s Appear
	1	6697807		2004-02-24	McGeachie		
	2	5915252		1999-06-22	Misheski et al.		
	3	6014670		2000-01-11	Zamanian et al.		
	4	6058394		2000-05-02	Bakow et al.		
	5	6134559		2000-10-17	Brumme et al.		
If you wisl	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevan s Appear
	1	20030158960		2003-08-21	Engberg		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		10562087
ing Date		
st Named Inventor John		McGeachie
t Unit		2167
aminer Name Not Y		et Assigned
amery Dealest Number		59160 020

	_									
	2	20030014318	2003-0	1-16	De La Motte e	tal				
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
			FOREIG	SN PAT	ENT DOCUM	ENTS	Remove	_		
Examiner Initial*	Cite No	Foreign Document Country Kind Publication Number Application Code ² i Code ⁴ Date Name of Patentee or Application Publication Passage				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS			
	1									
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add bu	tton Add	_		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Cite Initiats* Cite (Dook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), provided to the control of								T6		
	1	ORACLEA SALES AND MARKETING CONNECTED CUIENT USER'S GUIDE, Roleose 11, March 1998.								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
	EXAMINER SIGNATURE									
Eveniner	Class	t				Date Considered				

Ar

Б

1 See Kinz Codes of USPTO Patent Documents at year USPTO_CODE or MREP 901.04. ² Eaten office that insued the document, by the how-lefter code (WIPO Standard ST.3). ² Standard ST.3). ² or Justinese planted concurrents, by mandoon of the year of the Empore many personable several number of the plant occurrent, in a focus of the concurrent by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if Emploh languages the residention is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10562087
Filing Date		
First Named Inventor John		McGeachie
Art Unit		2167
Examiner Name	Not Y	et Assigned
Attorney Docket Number		58169-029

CERTIFICATION STATEMENT

Please see	37	CER 4	97	and	1 02	to	make the	a an	nrone	iata	cal	action	(e)	v

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David M. Mello/	Date (YYYY-MM-DD)	2006-04-06
Name/Print	David M. Mello	Registration Number	43799

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. D. 6th 1450, Alexandria, V.S. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.